ADMA Biologics Faces Valuation Shift Amid Declining Profit and Market Underperformance

ADMA Biologics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation. The company's valuation grade has shifted from expensive to very expensive, reflecting a notable change in its financial metrics. Currently, ADMA Biologics has a P/E ratio of 15, which is positioned against industry benchmarks that remain unspecified. The Price to Book Value stands at 4.62, while the EV to EBIT and EV to EBITDA ratios are recorded at 11.43 and 10.97, respectively. Additionally, the company's EV to Sales ratio is 4.29. Despite a robust return on capital employed (ROCE) of 41.35% and a return on equity (ROE) of 31.34%, the company has faced challenges, including a net profit of USD 94.71 million that has seen a decline of 32.37%. The inventory turnover ratio is at its lowest, recorded at 1 time, and the debtors turnover ratio is also low at 4.33 times. With a significant institutional holding of 100%, ADMA Biologics has underperformed the market over the past year, generating negative returns of -51.85%, contrasting sharply with the S&P 500's positive returns of 20.74%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.